Efficacy
toxicity, dermatitis, skin toxicity, skin toxicities
BREAST CANCER, HEAD AND NECK CANCER, SKIN TOXICITIES, ONCOLOGY, DERMATITIS, SKIN TOXICITY
All patients completed their follow-up records at 4 weeks post-radiotherapy. Of all patients, 55 patients (55.5%) experienced grade 1 skin toxicity, 30 patients (30.3%) experienced grade 2 toxicity, and 14 patients (14.1%) experienced grade 3 skin toxicity during the whole treatment and follow-up period. None of patients in this study experienced grade 4 RD. The incidence rate of ≥ grade 2 RD was 22% (95% confidence interval (CI), 12–36.3%) in Sanyrene group, as compared with 67.3% (95% CI, 52.3–79.6%) in the control intervention group (
Incidence rate of ≥ grade 2 of radiation dermatitis in two treatment group
RTOG skin toxicities in both groups [n (%)]RTOG, Radiation Therapy Oncology Group
Incidence rate of time to ≥ grade 2 of radiation dermatitis between two groups
Univariate and multivariate analysis for grade 2 skin toxicityTreatment Group(Sanyrene vs. Control intervention)HNC, head and neck cancer; BC, breast cancer; 3D-CRT, 3-dimensional conformal radiation therapy; VMAT, volumetric modulated arc radiation therapy; CCRT, Concurrent chemotherapyMean score of SD-16 were much higher in control intervention group than Sanyrene group at end of RT (25 vs.8.3), 2 weeks after RT (22.9 vs. 0.5) and 4 weeks after RT (4.2 vs.0), with significantly statistical difference between two groups (Fig. 
Mean score of SD-16 between two groups in whole treatment process